Meta-analysis in clinical trials¶
Why this mattered¶
DerSimonian and Laird’s 1986 paper mattered because it helped turn meta-analysis from an informal literature-summary practice into a practical statistical tool for clinical research. Its central contribution was the random-effects approach now commonly called the DerSimonian-Laird method: a simple way to combine trial results while allowing for genuine differences among studies, not merely sampling error within each study. That distinction was crucial for medicine, where trials often differ in populations, protocols, endpoints, doses, and clinical settings. The paper made it possible to ask not just “what is the average effect across trials?” but “how should evidence be synthesized when the trials are not estimating exactly the same underlying effect?”
The shift was methodological and institutional. Before this work, clinical trial evidence was often interpreted trial by trial, with narrative reviews vulnerable to selective emphasis and underpowered studies difficult to place in context. DerSimonian and Laird provided a usable framework for pooling randomized evidence in a way that acknowledged heterogeneity while remaining computationally accessible. This helped make quantitative evidence synthesis routine in clinical epidemiology, health technology assessment, guideline development, and later evidence-based medicine. Its influence is visible in the standard forest plot logic of modern systematic reviews: estimate each study’s effect, weight the evidence, quantify between-study variation, and present a pooled estimate with uncertainty.
The paper also shaped later breakthroughs by giving researchers a default baseline from which more sophisticated meta-analytic methods developed. Bayesian hierarchical meta-analysis, meta-regression, network meta-analysis, individual-patient-data meta-analysis, and improved estimators of between-study variance all address limitations or extensions of the same problem the paper made central: how to combine imperfect, heterogeneous evidence across studies. Even when later methods replace the original estimator, they often do so in a conceptual world that DerSimonian and Laird helped define. Its lasting importance is that it made cumulative medical evidence statistically operational.
Abstract¶
(no abstract available)
Related¶
- cite → Maximum Likelihood from Incomplete Data Via the EM Algorithm — The EM algorithm provides maximum-likelihood estimation machinery for handling incomplete or latent data structures relevant to meta-analytic clinical trial models.
- enables ← Maximum Likelihood from Incomplete Data Via the EM Algorithm — The EM algorithm enabled clinical-trial meta-analysis by providing a likelihood framework for estimating pooled effects with incomplete or latent study-level information.